DexCom (NASDAQ:DXCM) Price Target Raised to $90.00 at Wells Fargo & Company

DexCom (NASDAQ:DXCM) had its target price hoisted by Wells Fargo & Company from $80.00 to $90.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical device company’s stock.

Other research analysts have also recently issued research reports about the stock. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. UBS Group lowered their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. BTIG Research reduced their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Finally, JPMorgan Chase & Co. downgraded shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Price Performance

Shares of DXCM stock opened at $73.44 on Friday. The firm has a market cap of $29.21 billion, a price-to-earnings ratio of 47.38, a PEG ratio of 2.16 and a beta of 1.18. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a 50-day moving average price of $70.11 and a 200 day moving average price of $98.24.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The firm had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. Research analysts expect that DexCom will post 1.69 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Hedge funds have recently added to or reduced their stakes in the stock. Team Hewins LLC boosted its position in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after purchasing an additional 83 shares during the last quarter. Bleakley Financial Group LLC increased its stake in DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares during the last quarter. Capital Insight Partners LLC boosted its stake in DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after buying an additional 90 shares in the last quarter. HM Payson & Co. boosted its position in DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after buying an additional 100 shares during the period. Finally, State of Alaska Department of Revenue grew its position in DexCom by 0.3% during the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock worth $5,801,000 after acquiring an additional 105 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.